These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17031389)

  • 1. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
    Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
    Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
    Lu HR; Gallacher DJ; Yan GX
    J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
    Farkas AS; Nattel S
    Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
    Hondeghem LM; Carlsson L; Duker G
    Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
    Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
    J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
    Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P; Warner B
    J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
    Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
    J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
    Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
    J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
    Guo L; Dong Z; Guthrie H
    J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
    Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
    J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
    J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revisiting the hERG safety margin after 20 years of routine hERG screening.
    Leishman DJ; Abernathy MM; Wang EB
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
    Lu HR; Hermans AN; Gallacher DJ
    Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.